Latest News and Press Releases

177Lu-PSMA-I&T 및 64Cu-PSMA-I&T 의 일본 내 임상 개발, 규제 신청 및 상용화 추진 과정에서의 협력 포함양사 간 오랜 기간 형성된 관계를 바탕으로 파트너십 구축일본의 전립선암 신규 진단건수 매년 약 9만 건 수준 파리, Oct. 03, 2024 (GLOBE NEWSWIRE) --  핵의학 부문을 선도하는...

โดยเป็นความร่วมมือเพื่อพัฒนาทางคลินิก การยื่นเรื่องต่อหน่วยงานกำกับดูแล และการนำ 177Lu-PSMA-I&T และ 64Cu-PSMA-I&T...

Nội dung hợp tác bao gồm phát triển lâm sàng, hoàn thành hồ sơ pháp lý, và thương mại hóa các sản phẩm tại Nhật 177Lu-PSMA-I&T và 64Cu-PSMA-I&TXây dựng trên nền tảng quan hệ bên vững giữa hai...

Curium partners with PeptiDream for clinical development, regulatory filing, and commercialization of prostate cancer therapies in Japan.

Curium opens new Netherlands facility for Lu-177 production, ensuring a steady supply of this breakthrough cancer therapy isotope for over 100,000 patients

CURIUM ANNOUNCES PYLCLARI® – AN INNOVATIVE 18F-PSMA PET TRACER INDICATED IN PATIENTS WITH PROSTATE CANCER – IS NOW AVAILABLE IN SPAIN

PARIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Curium, líder mundial en medicina nuclear, ha anunciado hoy que PYLCLARI ® ya está disponible en España para pacientes con cáncer de próstata. PYLCLARI®...

Curium advances cancer care with its 505(b)(2) NDA submission to the FDA for Lutetium Lu 177 Dotatate Injection in GEP-NETS patients.

First doses of PYLCLARI® administered in Austria in early May 2024PYLCLARI® now available in France, Germany, Greece, Italy, and the Netherlands PARIS, June 17, 2024 (GLOBE NEWSWIRE) -- Curium, a...

Erste Dosen von PYLCLARI® werden Anfang Mai 2024 in Österreich verabreichtPYLCLARI® jetzt auch in Frankreich, Deutschland, Griechenland, Italien und den Niederlanden erhältlich PARIS, June 17, 2024 ...